Payment overview · 2025
General Payments
$293.51
16 reported records · 7 companies
Healthcare provider profile · identity verified
Matthew Stephen Higgins, MD
Allopathic & Osteopathic Physicians|Family Medicine · HENDERSON, NC · NPI 1962695395
Verified facts
What the public records show
CMS Open Payments records show Matthew Stephen Higgins, MD received $293.51 in general payments during 2025 across 16 reported records.
Novo Nordisk Inc accounted for 33.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $99.62 | 33.9% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $73.89 | 25.2% | 4 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $49.76 | 16.9% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $20.34 | 6.9% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.55 | 6.3% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.19 | 5.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.16 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $293.51 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.57 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.57 | 3 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $49.76 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.05 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.25 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.25 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $35.64 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $35.64 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $35.64 | 2 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 98 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
98 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
131 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 551 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 487 | 125 |
| Gabapentin | Gabapentin | 483 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 307 | 59 |
| Omeprazole | Omeprazole | 281 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 259 | 55 |
| Furosemide | Furosemide | 251 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 246 | 50 |
| Losartan Potassium | Losartan Potassium | 199 | 50 |
| Metformin Hcl | Metformin Hcl | 190 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 45 |
| Lisinopril | Lisinopril | 151 | 44 |
| Januvia | Sitagliptin Phosphate | 149 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 147 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 144 | 28 |
| Carvedilol | Carvedilol | 132 | 37 |
| Eliquis | Apixaban | 131 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 25 |
| Pregabalin | Pregabalin | 126 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 124 | 31 |
| Sertraline Hcl | Sertraline Hcl | 124 | 27 |
| Prednisone | Prednisone | 119 | 81 |
| Tramadol Hcl | Tramadol Hcl | 116 | 31 |
| Montelukast Sodium | Montelukast Sodium | 115 | 20 |
| Trazodone Hcl | Trazodone Hcl | 104 | 23 |
| Clonazepam | Clonazepam | 99 | 16 |
| Ozempic | Semaglutide | 98 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 25 |
| Allopurinol | Allopurinol | 89 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 88 | 16 |
| Metformin Hcl Er | Metformin Hcl | 86 | 22 |
| Symbicort | Budesonide/Formoterol Fumarate | 85 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 82 | 15 |
| Meloxicam | Meloxicam | 80 | 24 |
| Spironolactone | Spironolactone | 80 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 19 |
| Baclofen | Baclofen | 78 | 16 |
| Lorazepam | Lorazepam | 78 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 78 | 11 |
| Levetiracetam | Levetiracetam | 76 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 73 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 22 |
| Glipizide Er | Glipizide | 71 | 17 |
| Cefdinir | Cefdinir | 70 | 52 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 70 | 18 |
| Simvastatin | Simvastatin | 70 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 15 |
| Potassium Chloride | Potassium Chloride | 62 | 22 |
| Donepezil Hcl | Donepezil Hcl | 59 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 13 |
| Mirtazapine | Mirtazapine | 56 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 27 |
| Ibuprofen | Ibuprofen | 50 | 11 |
| Celecoxib | Celecoxib | 48 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 46 |
| Jardiance | Empagliflozin | 48 | 11 |
| Finasteride | Finasteride | 47 | 11 |
| Colchicine | Colchicine | 45 | 12 |
| Diazepam | Diazepam | 45 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 45 | 12 |
| Glipizide | Glipizide | 44 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Nystatin | Nystatin | 42 | 21 |
| Promethazine Hcl | Promethazine Hcl | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Fluconazole | Fluconazole | 40 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 11 |
| Torsemide | Torsemide | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Famotidine | Famotidine | 37 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 37 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Brilinta | Ticagrelor | 36 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Ketoconazole | Ketoconazole | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 36 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Belsomra | Suvorexant | 26 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Olanzapine-Fluoxetine Hcl | Olanzapine/Fluoxetine Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Tegretol Xr | Carbamazepine | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Neupro | Rotigotine | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $293.51 · 16 records | Novo Nordisk Inc | ABRYSVO, BEYFORTUS, COMIRNATY, CeQur Simplicity, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, NURTEC ODT, Ohtuvayre, Ozempic, PREVNAR 20, Rybelsus, UZEDY, VRAYLAR, Wegovy, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error